A Phase Ib trial of ROSgard (RMC-035) in patients at risk of acute kidney damage in connection with cardiac surgery
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs RMC 035 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; Pharmacodynamics
- 01 Nov 2018 According to an A1M Pharma AB media release, this study is expected to begin in the first half of 2020, with a planned result reading approximately six months after study start.
- 20 Sep 2018 New trial record
- 15 Aug 2018 According to an A1M Pharma AB media release, after completion of phase 1 trial in healthy volunteers this trial is planned in patient group.